Immune responses after live attenuated influenza vaccination
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs. However, our knowledge of the detailed immunological mechanisims induced by LAIV remain to be fully elucidated, and despite 14 years on the global market, there exists no correlate of protection. Recently, matters are further complicated by differing efficacy data from the US and Europe which are not understood. Better understanding of the immune responses after LAIV may aid in achieving the ultimate goal of a future "universal influenza vaccine". In this review we aim to cover the current understanding of the immune responses induced after LAIV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proceedings of the American philosophical society
(1838) · Journal of the Franklin Institute · doi:10.1016/s0016-0032(38)92229-x · Cited by 5,524
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Evolution and ecology of influenza A viruses
Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M., & Kawaoka, Y. (1992) · Microbiological Reviews · doi:10.1128/mr.56.1.152-179.1992 · Cited by 4,739
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213 · cited 1×
“Influenza viruses are a major cause of severe respiratory illness, and annually causes global fatality rates of 250,000-500,000 people, with an estimated 3-5 million hospitalizations [1-3].”
BackgroundEfficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789 · cited 1×
“ACCEPTED MANUSCRIPT 8 used, but is higher in children than adults and in vaccinees that experience influenza symptoms and have virological confirmed influenza [48-51].”
MethodThe annual impact of seasonal influenza in the US: Measuring disease burden and costs
Molinari, N.-A. M., Ortega-Sanchez, I. R., Messonnier, M. L., Thompson, W. W., Wortley, P. M., Weintraub, E., & Bridges, C. B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.046 · Cited by 1,722 · cited 1×
“In the US alone, the annual economic costs of influenza are estimated to $8 billion.(4) Pandemics cause a large burden on society and healthcare systems, often with higher morbidity and mortality rates in younger individuals, inducing a short-term global health emergency.”
BackgroundGrohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,632
(2016) · Japanese journal of leprosy · doi:10.5025/hansen.85.157 · Cited by 1,335
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,025 · cited 1×
“LAIV induces mucosal IgA antibodies, which provide protection at the site of viral entry against subsequent infection (Figure 1) [33-35].”
BackgroundWilkinson, T. M., Li, C. K. F., Chui, C. S. C., Huang, A. K. Y., Perkins, M., Liebner, J. C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2612 · Cited by 974 · cited 4×
“Important human studies have shown that CD4 + and CD8 + T-cells are important in limiting disease and may confer heterosubtypic immunity [61-63, 93].”
BackgroundMethodInfluential
Cited by
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Next-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
Metadata
- Authors
- Mohn, K. G.-I., Smith, I., Sjursen, H., & Cox, R. J.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2018-01-03
- Volume
- 14
- Issue
- 3
- Pages
- 571-578
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- OpenAlex
- W2756483320
- Cited by
- 178
- References
- 90
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune responses after live attenuated influenza vaccination. https://app.cochat.ai/papers/10.1080/21645515.2017.1377376
- The paper
- Mohn, K. G.-I., Smith, I., Sjursen, H., & Cox, R. J. (2018). Immune responses after live attenuated influenza vaccination. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2017.1377376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.